What question did this study set out to answer?

The aim is to develop a nanoplatform that enhances immune responses against tumors during chemotherapy.

G‐Quadruplex‐Modular CpG Nanoplatform Drives Multi‐Pathway Immunity for Abscopal Chemoimmunotherapy

View Full Paper

Ask AI

Bookmark

Authors

Demonstrates a novel nanoplatform driving immune activation in cancer, suggesting a new strategy for effective treatment.

The aim is to develop a nanoplatform that enhances immune responses against tumors during chemotherapy.
Developed a G-quadruplex-modular CpG nanoplatform using iron oxide nanoparticles.
Enabled sustained TLR9 pathway activation and targeted delivery of doxorubicin.
Activated the cGAS-STING pathway to modify the tumor microenvironment.
Achieved a primary tumor suppression rate of approximately 79.4% in murine models.
Promoted robust dendritic cell maturation and T cell infiltration.
Reprogrammed the tumor microenvironment into an immune-permissive state.

Sun et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark